Actelion (now Janssen Pulmonary Hypertension)

Actelion, now part of the Janssen Pharmaceutical Companies of Johnson & Johnson, was a prominent biopharmaceutical company focused on treating pulmonary arterial hypertension (PAH). Following its acquisition in June 2017, Actelion's expertise in PAH has been integrated into Janssen, enhancing its capabilities in this specialized market. Actelion was known for developing five of the thirteen marketed branded drugs for PAH, including endothelin receptor antagonists and prostacyclin analogs. These treatments play a vital role in managing PAH by addressing elevated pulmonary artery pressure and vascular resistance. Under Janssen, the commitment to pulmonary hypertension has expanded, emphasizing research, innovation in medical devices, and improved patient care through education and advocacy.